Table 1.
Patients' characteristics.
Figure 1.
Representative cc-TQ recording before and after acetazolamide challenge.
Vertical blue line indicates time of acetazolamide administration. cc-TQ–pial artery pulsation (cardiac component of the transillumination quotient).
Table 2.
Mean (± SE) values of cc-TQ, sas-TQ, MTT, CBV, CBF, TTP and PSV before and after acetazolamide challenge in hemisphere ipsilateral and contralateral to stenosis. The whole patient population (n = 15).
Table 3.
Mean (± SE) values of cc-TQ, sas-TQ, MTT, CBV, CBF, TTP and PSV before and after acetazolamide challenge in hemisphere ipsilateral and contralateral to stenosis. Patient population with cc-TQ ipsilateral/contralateral ratio ≥1 (n = 10).
Table 4.
Mean (± SE) values of cc-TQ, sas-TQ, MTT, CBV, CBF, TTP and PSV before and after acetazolamide challenge in hemisphere ipsilateral and contralateral to stenosis. Patient population with cc-TQ ipsilateral/contralateral ratio <1 (n = 5).
Table 5.
Comparison of mean (± SE) percentage changes after acetazolamide challenge versus baseline in patients with ipsilateral/contralateral cc-TQ ratio ≥1 and <1.